Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Oncternal Therapeutics Inc (ONCT)

Oncternal Therapeutics Inc (ONCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Oncternal Therapeutics Inc 12230 EL CAMINO REAL SUITE 230 SAN DIEGO CA 92130 USA

www.oncternal.com Employees: 30 P: 858-434-1113 F: 858-408-3010

Description:

Oncternal Therapeutics Inc. is a clinical-stage oncology company. It is engaged in developing treatments for cancers with critical unmet medical need. The company's pipeline includes cirmtuzumab, TK-216 and CAR-T therapy that targets ROR1 which are in clinical stage. Oncternal Therapeutics Inc., formerly known as GTx Inc., is based in San Diego, California.

Key Statistics

Overview:

Market Capitalization, $K 3,374
Enterprise Value, $K -3,326
Shares Outstanding, K 2,960
Annual Sales, $ 790 K
Annual Net Income, $ -39,480 K
Last Quarter Sales, $ 490 K
Last Quarter Net Income, $ -8,460 K
EBIT, $ -35,960 K
EBITDA, $ -37,590 K
60-Month Beta 1.33
% of Insider Shareholders 11.20%
% of Institutional Shareholders 16.05%
Float, K 2,628
% Float 88.80%
Short Volume Ratio 0.63

Growth:

1-Year Return -83.89%
3-Year Return -98.13%
5-Year Return -98.98%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 94.18%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -2.86 on 11/06/24
Next Earnings Date 11/14/24
Earnings Per Share ttm -11.69
EPS Growth vs. Prev Qtr 1.04%
EPS Growth vs. Prev Year 15.88%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 01/08/24

ONCT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -177.58%
Return-on-Assets % -131.30%
Profit Margin % -4,997.47%
Debt/Equity 0.00
Price/Sales 4.07
Price/Cash Flow N/A
Price/Book 0.35
Book Value/Share 3.09
Interest Coverage -2.10
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar